Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 4/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 4/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 4/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 4/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989026 | 0.85 | ABCC9 (0.49) | ABCC9ABCC8KCNJ11KCNJ8BRAF | |
| SCHEMBL6987810 | 0.85 | ABCC9 (0.47) | ABCC9ABCC8KCNJ11KCNJ8CYP11B1 | |
| SCHEMBL6984352 | 0.84 | ABCC9 (0.47) | ABCC9ABCC8KCNJ11KCNJ8MAPKAPK2 | |
| SCHEMBL6981921 | 0.84 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP11B1 | |
| SCHEMBL6983541 | 0.84 | MAPKAPK2 (0.52) | ABCC9ABCC8KCNJ11KCNJ8MAPKAPK2 | |
| SCHEMBL6984652 | 0.83 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8BRAF | |
| SCHEMBL6990454 | 0.83 | ABCC9 (0.52) | ABCC9ABCC8KCNJ11KCNJ8CYP11B1 | |
| SCHEMBL6988178 | 0.83 | NAMPT (0.52) | ABCC9ABCC8KCNJ11KCNJ8MAPKAPK2 | |
| SCHEMBL6989283 | 0.83 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8MAPKAPK2 | |
| SCHEMBL7555212 | 0.83 | ABCC9 (0.51) | ABCC9ABCC8KCNJ11KCNJ8MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | claimed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | claimed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | claimed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1358160-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6495576-B2 | N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| US-20020165264-A1 | Aminal diones as potassium channel openers | ABBOTT LABORATORIES | 2002-11-07 | — | — | US | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165264-A1 | Aminal diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | ABCC9 1043/4885ABCC8 705/4885KCNJ11 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.